Clazakizumab for kidney failure patients on dialysis
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called clazakizumab (CSL300) to see if it can reduce inflammation and lower the risk of heart problems in people with kidney failure who are on dialysis. It may help if you have diabetes or heart disease and have high inflammation levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been on dialysis for at least 12 weeks.
- Your blood test shows a high level of inflammation (hs-CRP at least 2.0 mg/L).
- You have diabetes or a history of heart disease/stroke (ASCVD).
- You are not currently taking drugs that suppress your immune system.
- You do not have a serious active infection or a history of certain infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called clazakizumab to see if it can reduce the risk of heart attacks, strokes, or cardiovascular death in people with high inflammation and certain chronic conditions like heart disease, diabetes, or kidney disease. Participation may help researchers learn if this treatment is safe and effective for this population.
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This trial tests a new drug called AZD7760 in two groups: healthy adults (Phase I) and adults with end-stage kidney disease who are on hemodialysis through a central venous catheter (Phase IIa). The goal is to see how safe the drug is and how the body processes it. This could lead to a new treatment option for people on dialysis.
This study tests how a new drug called CSL300 (clazakizumab) works in the body of people with end-stage kidney disease who are on dialysis. Researchers want to understand if it's safe and how your body processes it.
This trial tests three study drugs (called monoclonal antibodies) in people with end-stage kidney disease who are on hemodialysis. The goal is to see if these drugs are safe and how they affect your body while you're on dialysis.
Hear when a new End Stage Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.